Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes.
暂无分享,去创建一个
P. Goss | M. Crump | M. Prince | C. Girouard | M. Prince
[1] A. Luini,et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Bonadonna,et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.
[3] G. Bonadonna,et al. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.
[4] M. J. Caudell,et al. Detection of bone marrow involvement in breast cancer with magnetic resonance imaging. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] L. Norton,et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.
[6] R. Bast,et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Hortobagyi,et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin‐containing adjuvant therapy , 1992, Cancer.
[8] Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.
[9] D. Easton,et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. , 1991, European journal of cancer.
[10] D. Budman,et al. Adjuvant Therapy of Stage II Breast Cancer Treated with CMFVP, Radiation Therapy and VATH Following Lumpectomy A Pilot Trial , 1991, American journal of clinical oncology.
[11] A. Testori,et al. Comparison of long‐term survival of 1986 consecutive patients with breast cancer treated at the national cancer institute of milano, italy (1971 to 1972 and 1977 to 1978) , 1991, Cancer.
[12] R. Beveridge,et al. Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. , 1990, Journal of the National Cancer Institute.
[13] T. Powles,et al. Comparison of Different Trials of Adjuvant Chemotherapy in Stage II Breast Cancer Using a Natural History Data Base , 1987, American journal of clinical oncology.
[14] S. Feig. The role of new imaging modalities in staging and follow-up of breast cancer. , 1986, Seminars in oncology.
[15] A R Feinstein,et al. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.
[16] R. Weiss,et al. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.